Literature DB >> 23508518

Switching therapies in multiple sclerosis.

Patricia K Coyle1.   

Abstract

There are currently nine approved disease modifying therapies for relapsing forms of multiple sclerosis, with six distinct mechanisms of action. All have side effects, and none are cures. When a patient cannot tolerate therapy, or there is unacceptable breakthrough disease activity, the most common approach is to change drug. No universal guidelines exist for switching therapy. This overview will propose switch principles and suggestions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23508518     DOI: 10.1007/s40263-013-0042-5

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  65 in total

1.  Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Authors:  Bruce A C Cree; William H Stuart; Carlo S Tornatore; Douglas R Jeffery; Amy L Pace; Choon H Cha
Journal:  Arch Neurol       Date:  2011-04

2.  The management of multiple sclerosis in children: a European view.

Authors:  Angelo Ghezzi; Brenda Banwell; Alexey Boyko; Maria Pia Amato; Banu Anlar; Morten Blinkenberg; Maartje Boon; Massimo Filippi; Sergiusz Jozwiak; Immy Ketelslegers; Barbara Kornek; Ming Lim; Eva Lindstrom; Congor Nadj; Rinze Neuteboom; Maria A Rocca; Kevin Rostasy; Marc Tardieu; Evangeline Wassmer; Coriene Catsman-Berrevoets; Rogier Hintzen
Journal:  Mult Scler       Date:  2010-08-04       Impact factor: 6.312

3.  A method for evaluating treatment switching criteria in multiple sclerosis.

Authors:  Brian C Healy; Bonnie I Glanz; James Stankiewicz; Guy Buckle; Howard Weiner; Tanuja Chitnis
Journal:  Mult Scler       Date:  2010-08-24       Impact factor: 6.312

4.  Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

Authors:  S Belachew; R Phan-Ba; E Bartholomé; V Delvaux; I Hansen; P Calay; K E Hafsi; G Moonen; L Tshibanda; M Vokaer
Journal:  Eur J Neurol       Date:  2011-02       Impact factor: 6.089

5.  Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Authors:  L Daelman; A Maitrot; A Maarouf; M P Chaunu; C Papeix; A Tourbah
Journal:  Mult Scler       Date:  2012-08-20       Impact factor: 6.312

6.  Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Authors:  Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick
Journal:  Ann Neurol       Date:  2013-01       Impact factor: 10.422

7.  Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Authors:  M Trojano; F Pellegrini; D Paolicelli; A Fuiani; G B Zimatore; C Tortorella; I L Simone; F Patti; A Ghezzi; V Zipoli; P Rossi; C Pozzilli; G Salemi; A Lugaresi; R Bergamaschi; E Millefiorini; M Clerico; G Lus; M Vianello; C Avolio; P Cavalla; V Lepore; P Livrea; G Comi; M P Amato
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

8.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

9.  Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.

Authors:  E Portaccio; V Zipoli; G Siracusa; S Sorbi; M P Amato
Journal:  Eur Neurol       Date:  2009-01-08       Impact factor: 1.710

10.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

View more
  8 in total

1.  Quantitative MRI for Analysis of Active Multiple Sclerosis Lesions without Gadolinium-Based Contrast Agent.

Authors:  I Blystad; I Håkansson; A Tisell; J Ernerudh; Ö Smedby; P Lundberg; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-15       Impact factor: 3.825

Review 2.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

3.  CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.

Authors:  Scott D Newsome; Philip J Aliotta; Jacquelyn Bainbridge; Susan E Bennett; Gary Cutter; Kaylan Fenton; Fred Lublin; Dorothy Northrop; David Rintell; Bryan D Walker; Megan Weigel; Kathleen Zackowski; David E Jones
Journal:  Int J MS Care       Date:  2016 Nov-Dec

4.  A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Authors:  Tjalf Ziemssen; Ovidiu A Bajenaru; Adriana Carrá; Nina de Klippel; João C de Sá; Astrid Edland; Jette L Frederiksen; Olivier Heinzlef; Klimentini E Karageorgiou; Rafael H Lander Delgado; Anne-Marie Landtblom; Miguel A Macías Islas; Niall Tubridy; Yossi Gilgun-Sherki
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

5.  Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?

Authors:  Ricardo Alonso; María Bárbara Eizaguirre; Lucía Zavala; Cecilia Pita; Berenice Silva; Orlando Garcea
Journal:  J Clin Neurol       Date:  2018-07-30       Impact factor: 3.077

6.  The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis.

Authors:  Roberto De Masi; Stefania Orlando; Antonella De Donno
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-22

7.  The transition from first-line to second-line therapy in multiple sclerosis.

Authors:  Jan Dörr; Friedemann Paul
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.972

8.  Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.

Authors:  Christoph Kleinschnitz; Gabriele Niemczyk; Karin Rehberg-Weber; Colin Wernsdörfer
Journal:  Int J Mol Sci       Date:  2015-07-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.